PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an ext ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.Krystal Biotech (NASDAQ: KRYS ) has been on the Compounding Healthcare “Bio Boom” speculative portfolio since the investing group’s inception due to their ability to develop cutting-edge “redosable” gene therapies. Although I am a big believer in cell an ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

Core Insights - Krystal Biotech (KRYS) shares have increased by 15.8% over the past month, outperforming the industry growth of 4% [1] - The company reported fourth-quarter 2024 results with earnings exceeding estimates, although sales fell short [1] - The stock's surge post-earnings is attributed to strong uptake of Vyjuvek and positive pipeline developments [1] Vyjuvek Performance - Vyjuvek, the first FDA-approved gene therapy for dystrophic epidermolysis bullosa (DEB), was launched in May 2023 [3] - Sales of Vyjuvek reached $290.5 million, a significant increase from $50.7 million in 2023 [4] - As of February 2025, Krystal secured over 510 reimbursement approvals for Vyjuvek in the U.S., with 97% of lives covered under commercial and Medicaid plans [5] Regulatory Approvals - The European Medicines Agency has recommended the approval of Vyjuvek for DEB treatment [6] - A new drug application for Vyjuvek has been filed in Japan, with a decision expected in the second half of 2025 [6] Pipeline Developments - Krystal is advancing a pipeline of genetic medicines across various fields, including respiratory and oncology [7] - KB407 is being evaluated for cystic fibrosis, with interim data expected in mid-2025 [8] - KB408 is showing promising results for alpha-1 antitrypsin deficiency, with further assessments planned [9] Financial Metrics - KRYS shares currently trade at a price/sales ratio of 10.58x forward sales, lower than its historical mean of 22.83x [13] - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has risen to $7.07 from $5.40 over the past month [14] Cash Position - As of December 31, 2024, Krystal holds a cash balance of $749.6 million, positioning the company well for pipeline development [17] Market Position - Krystal Biotech holds a Zacks Rank 2 (Buy), indicating strong market confidence [18]

Krystal Biotech (KRYS) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Vyjuvek (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB). The intended DEB patient population includes those who have mutations in the COL7A1 gene starting from birth.DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. I ...

Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive recommendation for the approval of VYJUVEK for treating wounds in patients with dystrophic epidermolysis bullosa, with a final decision expected in the second quarter of 2025 [1][2]. Group 1: Product Information - VYJUVEK is a non-invasive, topical gene therapy designed to deliver two copies of the COL7A1 gene directly to DEB wounds, addressing the fundamental disease-causing mechanism [6]. - The therapy promotes durable wound closure and is suitable for patients from birth, with administration options available for trained patients or caregivers at home [1][4]. - VYJUVEK was previously approved in the United States in May 2023 for patients six months of age and older [6][9]. Group 2: Clinical Evidence - The CHMP's positive opinion is based on comprehensive clinical data from the Phase 1/2 GEM-1 and Phase 3 GEM-3 studies, which demonstrated successful COL7A1 gene delivery and durable wound closure [3]. - Long-term safety and efficacy are supported by results from an open-label extension study in the U.S. and real-world experience since the product's U.S. launch [3]. Group 3: Market Strategy - The company plans to launch VYJUVEK in Germany around mid-2025, followed by a launch in France later that year, aiming to maximize patient access [5]. - The approval by the EC would allow the company to market B-VEC under the registered European trademark VYJUVEK across the EU and additional countries [4].

Company Overview - Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to address diseases with high unmet medical needs [3] - The company's first commercial product, VYJUVEK®, is the first-ever redosable gene therapy and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa [3] - Krystal Biotech is advancing a robust pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3] Upcoming Events - The company will participate in the TD Cowen 45th Annual Health Care Conference on March 4, 2025, in Boston [1] - Krish S. Krishnan, the Chairman and CEO, will engage in a fireside chat at 1:50 pm ET and will host investor meetings throughout the day [1] - A webcast of the presentation will be available starting at 1:50 pm ET on March 4, 2025, and will be posted on the company's website [2]

Core Viewpoint - Investors are encouraged to consider Krystal Biotech, Inc. (KRYS) due to significant improvements in earnings estimates and positive short-term price momentum [1] Estimate Revisions - The upward trend in earnings estimate revisions indicates growing analyst optimism regarding Krystal Biotech's earnings prospects, which is expected to positively influence its stock price [2] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that stocks with a Zacks Rank 1 have generated an average annual return of +25% since 2008, highlighting the potential for Krystal Biotech [3] Current-Quarter Estimates - For the current quarter, Krystal Biotech is projected to earn $1.52 per share, reflecting a remarkable change of +4966.67% from the previous year's reported figure [4] - The Zacks Consensus Estimate for the company has increased by 21.2% over the last 30 days, with one estimate rising and no negative revisions [4] Current-Year Estimates - For the full year, the expected earnings per share for Krystal Biotech is $6.64, indicating a year-over-year increase of +121.33% [5] - In the past month, four estimates have been raised while one has been lowered, resulting in a 10.69% increase in the consensus estimate for the current year [5] Zacks Rank - Krystal Biotech currently holds a Zacks Rank 2 (Buy), reflecting favorable estimate revisions and the potential for strong performance compared to the S&P 500 [6] Investment Outlook - The stock has gained 21.4% over the past four weeks, driven by solid estimate revisions, suggesting that its earnings growth prospects may lead to further stock price increases [7]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score assesses a company's future growth potential based on earnings and sales [4] - Momentum Score tracks price trends to capitalize on upward or downward movements [5] - VGM Score combines all three styles to provide a comprehensive evaluation of stocks [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to identify strong investment opportunities [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [9] Stock Highlight: Krystal Biotech, Inc. (KRYS) - Krystal Biotech is a biotechnology company focused on genetic medicines for unmet medical needs [11] - KRYS holds a Zacks Rank of 2 (Buy) and a VGM Score of B, with a Momentum Style Score of A [11] - The stock has increased by 21.4% in the past four weeks, indicating strong momentum [11] - Recent upward revisions in earnings estimates for fiscal 2025 have raised the consensus estimate to $6.64 per share, reflecting a positive outlook [12]

Core Viewpoint - Krystal Biotech, Inc. (KRYS) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily based on a company's changing earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - The recent upgrade reflects an upward trend in earnings estimates, which is correlated with near-term stock price movements [3][5]. Impact of Institutional Investors - Changes in earnings estimates significantly influence institutional investors' valuation models, leading to buying or selling actions that affect stock prices [5]. - The rising earnings estimates for Krystal Biotech suggest an improvement in the company's underlying business, likely resulting in increased stock prices as investors respond positively [6]. Earnings Estimate Revisions - Empirical research supports a strong correlation between earnings estimate revisions and near-term stock movements, making tracking these revisions beneficial for investment decisions [7]. - The Zacks Rank system effectively utilizes earnings estimate revisions to classify stocks, with a proven track record of performance [8]. Specific Earnings Projections - Krystal Biotech is projected to earn $5.62 per share for the fiscal year ending December 2025, reflecting a year-over-year increase of 87.3% [9]. - Over the past three months, the Zacks Consensus Estimate for Krystal Biotech has increased by 3.1%, indicating growing analyst confidence [9]. Zacks Rating System Overview - The Zacks rating system maintains a balanced distribution of 'buy' and 'sell' ratings across its universe of over 4000 stocks, with only the top 20% receiving favorable ratings [10][11]. - The upgrade to Zacks Rank 2 positions Krystal Biotech among the top 20% of stocks in terms of earnings estimate revisions, suggesting potential for market-beating returns in the near term [11].